PL383287A1 - Lipides composition for production of lipid carrier for genetic medicines and its application - Google Patents

Lipides composition for production of lipid carrier for genetic medicines and its application

Info

Publication number
PL383287A1
PL383287A1 PL383287A PL38328707A PL383287A1 PL 383287 A1 PL383287 A1 PL 383287A1 PL 383287 A PL383287 A PL 383287A PL 38328707 A PL38328707 A PL 38328707A PL 383287 A1 PL383287 A1 PL 383287A1
Authority
PL
Poland
Prior art keywords
weight
production
composition
lipides
application
Prior art date
Application number
PL383287A
Other languages
Polish (pl)
Other versions
PL208054B1 (en
Inventor
Aleksander F. Sikorski
Paulina Wyrozumska
Marta Walasek
Kazimierz Kuliczkowski
Original Assignee
Uniwersytet Wrocławski
Akademia Medyczna im. Piastów Śląskich we Wrocławiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Wrocławski, Akademia Medyczna im. Piastów Śląskich we Wrocławiu filed Critical Uniwersytet Wrocławski
Priority to PL383287A priority Critical patent/PL208054B1/en
Priority to PCT/PL2008/000062 priority patent/WO2009031911A1/en
Publication of PL383287A1 publication Critical patent/PL383287A1/en
Publication of PL208054B1 publication Critical patent/PL208054B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych charakteryzuje się tym, że zawiera 38,7% wagowych fosfatydylocholiny (PC), 15,4% wagowych distearoilofosfatydyloetanoloaminowej pochodnej glikolu polietylenowego 2000 (sól amonowa) (DSPE-PEG), od 10,9 do 16,8% wagowych dioleiolofosfatydyloetanolaminy (DOPE), od 4,05 do 6,75% wagowych 3ß-N-dimetyloetanokarbamoilo cholesterolu (DC-CHOL) i od 23,4 do 30,6% wagowych soli trimetyloamoniowej 1,2 -dioleilopropanu (DOTAP), przy czym PC, DOPE i DC-CHOL stanowią zewnętrzna błonę nośnika, a DOTAP wchodzi skład rdzenia nośnika zamkniętego w jego wnętrzu.The lipid composition for the production of a lipid carrier for genetic drugs is characterized in that it comprises 38.7% by weight of phosphatidylcholine (PC), 15.4% by weight of distearoylphosphatidylethanolamine derivative of polyethylene glycol 2000 (ammonium salt) (DSPE-PEG), from 10.9 to 16.8% by weight of dioleoylphosphatidylethanolamine (DOPE), from 4.05 to 6.75% by weight of 3β-N-dimethylethanecarbamoyl cholesterol (DC-CHOL) and from 23.4 to 30.6% by weight of trimethylammonium salt of 1,2-dioleylpropane ( DOTAP), where PC, DOPE and DC-CHOL are the outer membrane of the carrier, and DOTAP is part of the core of the carrier enclosed inside it.

PL383287A 2007-09-06 2007-09-06 Lipides composition for production of lipid carrier for genetic medicines and its application PL208054B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL383287A PL208054B1 (en) 2007-09-06 2007-09-06 Lipides composition for production of lipid carrier for genetic medicines and its application
PCT/PL2008/000062 WO2009031911A1 (en) 2007-09-06 2008-09-02 Cationic liposome carrier for genetic drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL383287A PL208054B1 (en) 2007-09-06 2007-09-06 Lipides composition for production of lipid carrier for genetic medicines and its application

Publications (2)

Publication Number Publication Date
PL383287A1 true PL383287A1 (en) 2009-03-16
PL208054B1 PL208054B1 (en) 2011-03-31

Family

ID=40325840

Family Applications (1)

Application Number Title Priority Date Filing Date
PL383287A PL208054B1 (en) 2007-09-06 2007-09-06 Lipides composition for production of lipid carrier for genetic medicines and its application

Country Status (2)

Country Link
PL (1) PL208054B1 (en)
WO (1) WO2009031911A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177421A2 (en) * 2012-05-23 2013-11-28 The Ohio State University Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same
US10253315B2 (en) * 2012-08-30 2019-04-09 Commissariat A L'energie Atomique Et Aux Energies Alternatives Method for transfection of nucleic acids into eukaryotic cells in 3D scaffold
PL233741B1 (en) 2014-04-18 2019-11-29 Wroclawskie Centrum Badan Eit Spolka Z Ograniczona Odpowiedzialnoscia Lipid composition serving for the creation of the genetic medicines carrier managed by means of antibodies and its application
PL407947A1 (en) * 2014-04-18 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Oriented, liposome form of the polyethyleneimine oligonucleotide, its application and method for obtaining it
WO2017220099A1 (en) 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants with modified drainage properties
CN110101664A (en) * 2019-05-06 2019-08-09 西安交通大学医学院第一附属医院 For delivering the system of nucleic acid drug and preparation method thereof with specific cleavage HPV16 type gene function
CN111603571A (en) * 2020-05-28 2020-09-01 中国药科大学 Mitochondrion targeting lipid-like carrier Mito-Alisposome, compound thereof, preparation method and application
CN114699420A (en) * 2022-03-08 2022-07-05 南方科技大学 Composition for treating prostate cancer and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1017365T3 (en) * 1997-06-23 2004-03-29 Alza Corp Liposome enclosed polynucleotide composition and method
US7390780B2 (en) * 1999-04-23 2008-06-24 Alza Corporation Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification
JP2004535388A (en) * 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション Lipid-containing drug delivery conjugates and methods for their production

Also Published As

Publication number Publication date
PL208054B1 (en) 2011-03-31
WO2009031911A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
PL383287A1 (en) Lipides composition for production of lipid carrier for genetic medicines and its application
Schlich et al. Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles
Cullis et al. Lipid nanoparticle systems for enabling gene therapies
Zheng et al. Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm
Rajesh et al. Dramatic influence of the orientation of linker between hydrophilic and hydrophobic lipid moiety in liposomal gene delivery
Grijalvo et al. Cationic niosomes as non-viral vehicles for nucleic acids: Challenges and opportunities in gene delivery
Bajaj et al. Design, synthesis, and in vitro gene delivery efficacies of novel cholesterol-based gemini cationic lipids and their serum compatibility: A structure− activity investigation
Hmingthansanga et al. Improved topical drug delivery: Role of permeation enhancers and advanced approaches
Gomes-da-Silva et al. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges
Mochizuki et al. The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine
JP2014529328A5 (en)
Pedro et al. Ionic liquids in drug delivery
MX2019011004A (en) Compounds and compositions for intracellular delivery of therapeutic agents.
Koynova et al. Hydrophobic moiety of cationic lipids strongly modulates their transfection activity
WO2012091523A3 (en) Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
Sun et al. Enhancing the therapeutic delivery of oligonucleotides by chemical modification and nanoparticle encapsulation
Moraes et al. miRNA delivery by nanosystems: state of the art and perspectives
MY151268A (en) Novel thermosensitive liposomes containing therapeutic agents
Munoz-Ubeda et al. Effect of lipid composition on the structure and theoretical phase diagrams of DC-Chol/DOPE-DNA lipoplexes
Campani et al. Lipid nanovectors to deliver RNA oligonucleotides in cancer
EP4043040A8 (en) Small liposomes for delivery of immunogen-encoding rna
WO2012122313A3 (en) Targeted nanocarrier systems for delivery of actives across biological membranes
Sen et al. Design, syntheses, and transfection biology of novel non-cholesterol-based guanidinylated cationic lipids
Gaucheron et al. Synthesis and properties of novel tetraalkyl cationic lipids
Nantz et al. The benefit of hydrophobic domain asymmetry on the efficacy of transfection as measured by in vivo imaging